New hope for Tough-to-Treat ovarian cancers: immune therapy trial
NCT ID NCT03355976
Summary
This study is testing whether two immunotherapy drugs, nivolumab alone or combined with ipilimumab, can help control recurrent clear cell ovarian, fallopian tube, and related cancers. It will enroll 46 patients whose cancer has returned after standard chemotherapy. The main goal is to see how many patients' tumors shrink significantly from these treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
University of Illinois Chicago
Chicago, Illinois, 60612, United States
-
Women & Infants Hospital
Providence, Rhode Island, 02905, United States
Conditions
Explore the condition pages connected to this study.